UC BIOSPHERE BAVENCIO® (avelumab) Summit, taking place virtually on:
NOVEMBER 16, 2021
In May of 2021, oncologists gathered from around the world to virtually attend the inaugural UC BIOSPHERE SUMMIT to hear discussions and insights on data in first-line maintenance therapy for eligible patients with advanced UC. We are pleased to continue the meeting series with another invitation-only event!
The next UC BIOSPHERE Summit will be an immersive and engaging opportunity to hear important data from leading experts in UC! The meeting will bring together oncologists who share a common interest in bringing the standard of care to their patients.
Join one of three LIVE BROADCASTS on November 16, 2021
• ASIA-PACIFIC BROADCAST | 18:00 JST
• EUROPE BROADCAST | 18:00 CET
• THE AMERICAS BROADCAST | 18:00 EST
This event is exclusive to healthcare professionals and is initiated, organized, and sponsored by the Alliance between Merck KGaA, Darmstadt, Germany and Pfizer.
The information presented during this meeting is intended for an international audience. Product related information is based on the European Medicines Agency (EMA)-approved Summary of Product Characteristics (SmPC) for BAVENCIO® (avelumab). Click here to access the EMA approved SmPC. If you are a healthcare professional from outside of the European Economic Area please refer to your local product information.
If you are a healthcare professional from Japan, click here to access the Japan approved package insert for BAVENCIO® (avelumab).
GL-AVEBL-00170 October 2021